Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Aug 7, 2018

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

Jul 31, 2018

ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'

Jul 10, 2018

ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference

Jun 28, 2018

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Jun 26, 2018

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

Jun 20, 2018

ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting

Jun 12, 2018

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease

May 11, 2018

ProMIS Neurosciences Announces First Quarter 2018 Results

May 1, 2018

ProMIS Neurosciences Closes $7.2 Million Private Placement

Apr 10, 2018

ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease

  • arrow_back
  • 1…
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy